Search - tctmd.com

Displaying 1 - 10 of 10

Sort: Relevancy | Date

News Industry News

Intact Vascular Announces Positive One-Year Data from TOBA III Clinical Trial

September 27, 2019

DCB Match DES Through 1 Year in Femoropopliteal Lesions, DRASTICO Affirms

News Daily News

DCB Match DES Through 1 Year in Femoropopliteal Lesions, DRASTICO Affirms

July 11, 2019

TCTMD’s Top 10 Most Popular Stories for June 2019

News Daily News

TCTMD’s Top 10 Most Popular Stories for June 2019

June 28, 2019

FDA Review Affirms Mortality Signal With Paclitaxel-Based Devices for PAD Ahead of Panel Meeting

News Daily News

FDA Review Affirms Mortality Signal With Paclitaxel-Based Devices for PAD Ahead of Panel Meeting

June 10, 2019

Supervised Exercise Plus Angioplasty Best for Intermittent Claudication: Meta-analysis

News Daily News

Supervised Exercise Plus Angioplasty Best for Intermittent Claudication: Meta-analysis

June 03, 2019

TCTMD’s Top 10 Most Popular Stories for May 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for May 2019

May 31, 2019

Paclitaxel DCBs and CHIP: SCAI Kicks Off With Two Hot-Potato Topics

News Conference News SCAI 2019

Paclitaxel DCBs and CHIP: SCAI Kicks Off With Two Hot-Potato Topics

Yael L. Maxwell

May 21, 2019

SAFE-DCB Demonstrates Consistent Efficacy at 1 Year in Real-world Femoropopliteal Disease Patients

News Conference News CRT 2019

SAFE-DCB Demonstrates Consistent Efficacy at 1 Year in Real-world Femoropopliteal Disease Patients

Yael L. Maxwell

March 14, 2019

Acknowledgment of Safety Signal for Paclitaxel Devices in PAD May Mark Sea Change in Controversy

News Conference News CRT 2019

Acknowledgment of Safety Signal for Paclitaxel Devices in PAD May Mark Sea Change in Controversy

March 06, 2019

REAL PTX: Head-to-Head DCB, DES Data in PAD Show Trend Favoring Stenting at 36 Months

News Daily News

REAL PTX: Head-to-Head DCB, DES Data in PAD Show Trend Favoring Stenting at 36 Months

February 11, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.